Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Johnson and Johnson
Accenture
Citi
US Army
AstraZeneca
Merck
Chubb
Dow

Generated: October 20, 2017

DrugPatentWatch Database Preview

Bristol Myers Company Profile

« Back to Dashboard

What is the competitive landscape for BRISTOL MYERS, and when can generic versions of BRISTOL MYERS drugs launch?

BRISTOL MYERS has eighty-three approved drugs.

There are eighteen US patents protecting BRISTOL MYERS drugs and there have been three Paragraph IV challenges on BRISTOL MYERS drugs in the past three years.

There are four hundred and fifty-five patent family members on BRISTOL MYERS drugs in fifty-eight countries and one hundred and sixty-six supplementary protection certificates in fifteen countries.

Summary for Applicant: Bristol Myers

International Patents:455
US Patents:18
Tradenames:71
Ingredients:61
NDAs:83
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb
GLUCOPHAGE XR
metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL021202-004Apr 11, 2003ABRXYesYes► Subscribe► Subscribe ► Subscribe
Bristol Myers Squibb
VIDEX
didanosine
FOR SOLUTION;ORAL020155-003Oct 9, 1991DISCNNoNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
GLUCOVANCE
glyburide; metformin hydrochloride
TABLET;ORAL021178-001Jul 31, 2000DISCNYesNo► Subscribe► SubscribeY► Subscribe
Bristol Myers Squibb
REYATAZ
atazanavir sulfate
CAPSULE;ORAL021567-001Jun 20, 2003DISCNYesNo► Subscribe► SubscribeY► Subscribe
Bristol Myers Squibb
GLUCOVANCE
glyburide; metformin hydrochloride
TABLET;ORAL021178-003Jul 31, 2000DISCNYesNo► Subscribe► SubscribeY► Subscribe
Bristol Myers Squibb
MONOPRIL-HCT
fosinopril sodium; hydrochlorothiazide
TABLET;ORAL020286-001Nov 30, 1994DISCNYesNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
TESLAC
testolactone
TABLET;ORAL016118-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
VIDEX
didanosine
TABLET, CHEWABLE;ORAL020154-003Oct 9, 1991DISCNYesNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
AZACTAM
aztreonam
INJECTABLE;INJECTION050580-002Dec 31, 1986APRXYesYes► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
SUSTIVA
efavirenz
CAPSULE;ORAL020972-003Sep 17, 1998RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Bristol Myers

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol Myers Squibb
PRAVACHOL
pravastatin sodium
TABLET;ORAL019898-004Mar 22, 1993► Subscribe► Subscribe
Bristol Myers Squibb
VIDEX EC
didanosine
CAPSULE, DELAYED REL PELLETS;ORAL021183-003Oct 31, 2000► Subscribe► Subscribe
Bristol Myers Squibb
VIDEX
didanosine
TABLET, CHEWABLE;ORAL020154-003Oct 9, 1991► Subscribe► Subscribe
Bristol Myers Squibb
BARACLUDE
entecavir
TABLET;ORAL021797-002Mar 29, 2005► Subscribe► Subscribe
Bristol Myers Squibb
PRAVACHOL
pravastatin sodium
TABLET;ORAL019898-008Dec 18, 2001► Subscribe► Subscribe
Bristol Myers Squibb
BUSPAR
buspirone hydrochloride
TABLET;ORAL018731-003Apr 22, 1996► Subscribe► Subscribe
Bristol Myers Squibb
PRAVIGARD PAC (COPACKAGED)
aspirin; pravastatin sodium
TABLET, TABLET, TABLET;ORAL021387-001Jun 24, 2003► Subscribe► Subscribe
Bristol Myers Squibb
VIDEX
didanosine
FOR SOLUTION;ORAL020155-005Oct 9, 1991► Subscribe► Subscribe
Bristol Myers Squibb
VIDEX
didanosine
TABLET, CHEWABLE;ORAL020154-003Oct 9, 1991► Subscribe► Subscribe
Bristol Myers Squibb
ZERIT
stavudine
CAPSULE;ORAL020412-001Jun 24, 1994► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for BRISTOL MYERS drugs

Drugname Dosage Strength Tradename Submissiondate
apixaban
Tablets2.5 mg and 5 mg
ELIQUIS
12/28/2016
efavirenz
Capsules50 mg, 100 mg and 200 mg
SUSTIVA 
11/3/2016
naloxone hydrochloride
Nasal Spray4 mg/spray
NARCAN
7/15/2016
dasatinib
Tablets80 mg and 140 mg
SPRYCEL
6/17/2011
dasatinib
Tablets80 mg and 140 mg
SPRYCEL
6/16/2011
dasatinib
Tablets20 mg, 50 mg, 70 mg and 100 mg
SPRYCEL
6/28/2010
entecavir
Tablets0.5 mg and 1 mg
BARACLUDE
6/14/2010
atazanavir sulfate
Capsules100 mg and 150 mg
REYATAZ
3/19/2010
atazanavir sulfate
Capsules200 mg
REYATAZ
2/16/2010
atazanavir sulfate
Capsules300 mg
REYATAZ
7/20/2009
efavirenz
Tablets600 mg
SUSTIVA
4/9/2009
pravastatin sodium
Tablets30 mg
PRAVACHOL
6/1/2005
didanosine
Delayed-release Capsules200 mg, 250 mg and 400 mg
VIDEX EC
6/1/2004

Non-Orange Book Patents for Bristol Myers

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,673,810 Imidazo-heterobicycles as factor Xa inhibitors► Subscribe
7,005,435Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
6,989,391Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
5,965,729 Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent► Subscribe
7,371,761Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
6,110,946 Antivirally active heterocyclic azahexane derivatives► Subscribe
7,091,223Cyclic protein tyrosine kinase inhibitors► Subscribe
8,188,120Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
7,531,535Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
7,189,854Cyclic protein tyrosine kinase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Bristol Myers Drugs

Country Document Number Estimated Expiration
South Korea20080075927► Subscribe
Japan2017039768► Subscribe
Turkey200102969► Subscribe
Austria544750► Subscribe
Georgia, Republic ofP20074098► Subscribe
New Zealand601738► Subscribe
Netherlands300203► Subscribe
Australia735875► Subscribe
Brazil0009721► Subscribe
New Zealand506202► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Bristol Myers Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0001France► SubscribePRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804
00221Netherlands► SubscribePRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
/2000Austria► SubscribePRODUCT NAME: INSULIN ASPART/PROTAMIN; NAT. REGISTRATION NO/DATE: EU/1/00/142/001-008 20000801; FIRST REGISTRATION: LI 55414-55416 20000623
C0040France► SubscribePRODUCT NAME: ENTECAVIR; REGISTRATION NO/DATE: EU/1/06/343/001 20060626
/2000Austria► SubscribePRODUCT NAME: EFAVIRENZ, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES; NAT. REGISTRATION NO/DATE: EU/1/99/110/001-004 1/99/111/001-004 19990528; FIRST REGISTRATION: LI 54908 01, 54908 02, 54908 03 19981120
2009004,C0770388Lithuania► SubscribePRODUCT NAME: ESTRADIOLI VALERAS + DIENOGESTUM; NAT. REGISTRATION NO/DATE: LT/1/09/1512/001, 2009 04 06 LT/1/09/1512/002, 2009 04 06 LT/1/09/1512/003 20090406; FIRST REGISTRATION: BE 327792 20081103
2009Austria► SubscribePRODUCT NAME: KOMBINATION AUS ESTRADIOLVALERAT UND DIENOGEST; NAT. REGISTRATION NO/DATE: 1-28003 20090203; FIRST REGISTRATION: BE BE 327792 20081103
00597Netherlands► SubscribePRODUCT NAME: INSULINE DEGLUDEC EN INSULINE ASPART; REGISTRATION NO/DATE: EU/1/12/806/001EU/1/12/806/004EU/1/12/806/005EU/1/12/806/007EU/1/12/806/008 2013210121
C0039Belgium► SubscribePRODUCT NAME: STAVUDINE; REGISTRATION NO/DATE: EU/1/96/009/001 19960508
11/032Ireland► SubscribePRODUCT NAME: APIXABAN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/11/691/001-005 20110518
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
US Department of Justice
Merck
Johnson and Johnson
Novartis
Teva
McKinsey
Mallinckrodt
Queensland Health
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot